134 related articles for article (PubMed ID: 34558826)
1. Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
Rohr-Udilova N; Tsuchiya K; Timelthaler G; Salzmann M; Meischl T; Wöran K; Stift J; Herac M; Schulte-Hermann R; Peck-Radosavljevic M; Sieghart W; Eferl R; Jensen-Jarolim E; Trauner M; Pinter M
Hepatol Commun; 2021 Nov; 5(11):1939-1952. PubMed ID: 34558826
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
3. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
4. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
[TBL] [Abstract][Full Text] [Related]
7. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
10. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
11. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
[TBL] [Abstract][Full Text] [Related]
14. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
15. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria.
Parisi I; Tsochatzis E; Wijewantha H; Rodríguez-Perálvarez M; De Luca L; Manousou P; Fatourou E; Pieri G; Papastergiou V; Davies N; Yu D; Luong T; Dhillon AP; Thorburn D; Patch D; O'Beirne J; Meyer T; Burroughs AK
Liver Transpl; 2014 Nov; 20(11):1327-35. PubMed ID: 25088400
[TBL] [Abstract][Full Text] [Related]
17. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria.
Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH
Transplant Proc; 2012 Oct; 44(8):2459-61. PubMed ID: 23026620
[TBL] [Abstract][Full Text] [Related]
19. Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.
Jiang Z; Jiang Q; Fang X; Wang P; Que W; Li H; Yu Y; Liu X; Wang C; Zhong L
BMC Cancer; 2021 May; 21(1):521. PubMed ID: 33964921
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
